GlassScriptPhysician profile
Benjamin James Kahn
NPI 1457811275
$4,378.42
in general payments reported to CMS, 2019-2025
25 companies · $2,065 in 2025
The $2,065 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $198 · 2024: $1,985 · 2025: $2,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,170 · Travel and Lodging: $62.50 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,169.77 |
| Travel and Lodging | $62.50 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $763.10 | 2024-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $612.82 | 2024-2025 | Dupixent |
| Dermavant Sciences, INC. | $516.32 | 2024 | Vtama |
| Janssen Scientific Affairs, LLC | $419.65 | 2024-2025 | Tremfya |
| Ucb, INC. | $287.00 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $254.83 | 2022-2025 | Aklief, Nemluvio |
| Incyte Corporation | $235.21 | 2024 | Opzelura |
| Journey Medical Corporation | $219.08 | 2024-2025 | |
| Lilly USA, LLC | $186.67 | 2025 | Ebglyss, Taltz |
| Janssen Biotech, INC. | $180.87 | 2025 | Tremfya |
| Amgen INC. | $167.62 | 2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $106.83 | 2024-2025 | Sotyktu |
| Kerecis Limited | $68.65 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Organogenesis INC. | $56.94 | 2024-2025 | Affinity, Cygnus Dual |
| Pfizer INC. | $54.42 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $47.14 | 2025 | |
| Smith+Nephew, INC. | $39.02 | 2025 | Grafix Pl |
| Arcutis Biotherapeutics, INC. | $36.32 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $34.82 | 2025 | |
| Biofrontera INC. | $19.68 | 2025 | |
| Convatec INC. | $19.08 | 2024 | |
| Leo Pharma INC. | $16.53 | 2025 | Adbry |
| Almirall LLC | $15.43 | 2024 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.20 | 2023 | Spevigo |
| Organon LLC | $5.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.